Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Non-Current Deferred Tax Liability (2019 - 2021)

Allogene Therapeutics' Non-Current Deferred Tax Liability history spans 2 years, with the latest figure at $11.7 million for Q4 2020.

  • For Q4 2020, Non-Current Deferred Tax Liability fell 11.2% year-over-year to $11.7 million; the TTM value through Dec 2020 reached $11.7 million, down 11.2%, while the annual FY2020 figure was $11.7 million, 11.2% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2020 was $11.7 million at Allogene Therapeutics, down from $13.2 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $13.2 million in Q4 2019 and bottomed at $11.7 million in Q4 2020.